A Phase 1/2 interventional study of AD-303A and AD-3031 in Androgenetic Alopecia, sponsored by Moogene Medi Co., Ltd. Not yet recruiting at 1 site in South Korea. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Moogene Medi Co., Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Alopecia with a site in Korea, Republic of — 5 open to participants now, 5 under way, 3 of them phase 3. Alopecia · Korea, Republic of.
Among the 22 studies in Alopecia with a site in Korea, Republic of, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1/2, and was the 20th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →5 of the 22 studies in Alopecia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Epibiotech · Sites in Korea, Republic of
Ages 19+
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 18–50 · Men only
Pfizer · Sites in Korea, Republic of, United States, Canada and 8 more countries
Ages 12+
Eli Lilly and Company · Sites in Korea, Republic of, United States, Argentina and 9 more countries
Ages 6–17
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 19 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 80 across the 21 interventional studies, 712 across the 1 observational. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 22 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Moogene Medi Co., Ltd as lead sponsor.
Moogene Medi Co., Ltd has 1 study filed under Alopecia — fewer than ten, so there is no comparison to draw.
1 of the studies in Alopecia with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06916793Phase 3Chong Kun Dang PharmaceuticalA Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Alopecia with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive topical AD-303A applied to the scalp according to the study protocol.
Drug: AD-303A
Participants receive oral AD-3031 administered according to the study protocol.
Drug: AD-3031
Topical AD-303A applied to the scalp according to the study protocol.
Oral AD-3031 administered according to the study protocol.
Maximum observed plasma concentration (Cmax) of dutasteride
The maximum observed plasma concentration (Cmax) of dutasteride following administration of the study drug.
Time frame: Up to Day14
Change from baseline in scalp dihydrotestosterone (DHT) concentration Description
Change from baseline in scalp tissue dihydrotestosterone (DHT) concentration measured following repeated administration of topical dutasteride.
Time frame: Baseline to Day 8
Plan to share: No — Phase 1/2a
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Sep 2026, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.